^
    23h
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    1d
    ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
    P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date • First-in-human
    |
    JZP3507
    1d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Immunolight, LLC | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Sep 2025 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    methoxsalen (X-PACT)
    1d
    Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities (clinicaltrials.gov)
    P1, N=9, Terminated, Wake Forest University Health Sciences | N=27 --> 9 | Recruiting --> Terminated; Terminated due to low accruals
    Enrollment change • Trial termination
    |
    gemcitabine • docetaxel
    1d
    INSIGHT: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (clinicaltrials.gov)
    P3, N=54, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    imatinib • sunitinib • Qinlock (ripretinib)
    2d
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    2d
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Active, not recruiting | Initiation date: May 2026 --> Dec 2025
    Enrollment closed • Trial initiation date
    |
    zanzalintinib (XL092)
    2d
    Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma. (PubMed, Commun Biol)
    scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET overexpression • ALK fusion
    2d
    A case report of retroperitoneal infantile fibrosarcoma with RBPMS-NTRK3 fusion gene positivity (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
    Initial chemotherapy with the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) was administered, but the response was poor. To our knowledge, this is the first reported case of infantile fibrosarcoma with RBPMS-NTRK3 fusion in China. Treatment with larotrectinib resulted in marked tumor shrinkage.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • RBPMS (RNA-binding protein with multiple splicing)
    |
    Vitrakvi (larotrectinib) • cyclophosphamide • vincristine • dactinomycin
    2d
    Functional MRI quantitative parameters as biomarkers of proliferation in synovial sarcoma xenografts: A study based on precise MR imaging-pathology correlation. (PubMed, Magn Reson Imaging)
    The proliferative activity of SS xenografts could be assessed using quantitative parameters derived from IVIM and DCE-MRI.
    Journal
    |
    PTEN (Phosphatase and tensin homolog)
    2d
    Multifunctional scaffold integrating chemo/photothermal therapy and bone defect reconstruction for osteosarcoma: An in vitro evaluation. (PubMed, Colloids Surf B Biointerfaces)
    Doxorubicin (DOX) forms stable π-π stacking complexes with PDA, creating a versatile chemotherapeutic delivery platform...We hypothesize that this integrated approach will demonstrate enhanced antitumor efficacy while promoting functional bone reconstruction. Comprehensive in vitro evaluations will elucidate the underlying mechanisms and provide preclinical validation for this precision oncology strategy.
    Preclinical • Journal
    |
    BMP2 (Bone Morphogenetic Protein 2)
    |
    doxorubicin hydrochloride
    2d
    A Study of Pembrolizumab in People With Ultra-Rare Sarcomas (clinicaltrials.gov)
    P2, N=32, Recruiting, Memorial Sloan Kettering Cancer Center | Not yet recruiting --> Recruiting | Trial completion date: Aug 2028 --> Dec 2028 | Trial primary completion date: Aug 2028 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date • Pan tumor
    |
    Keytruda (pembrolizumab)